Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test

Brinser JH. Ocular Bacteriology. In: Tabbara KF, Hyndiuk RA, editors. Infections of the Eye. 2nd Boston: Little, Brown and Company; 1996. p. 123-51.

Thornsberry, 1997, Diagn Microbiol Infect Dis, Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory section, 249

Appelbaum, 1992, Clin Infect Dis, Antimicrobial resistance in Streptococcus pneumoniae: an overview, 77

Zhanel, 2001, J Antimicrob Chemother, In vitro pharmocodynamic modeling simulating free serum concentrations of fluoroquinolones against multi-drug resistant Streptococcus pneumoniae, 435

Tankovic, 1996, Antimicrob Agents Chemother, Contribution of mutations in gyr A and par C genes to fluoroquinolones resistance of mutatnts of Streptococcus pneumoniae obtained in vivo and in vitro, 2505

Chen, 1999, N Engl J Med, Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada, 233

Zhanel, 2002, J Antimicrb Chemother, Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae, 807

Wilhemus KR, Liesegang TJ, Osato MS, Jones DB. Laboratory Diagnosis of Ocular Infections. In: Spector SC, editor. CUMITECH. Washingdon DC: American Society for Microbiology; 1994.

Byrne KA, Burd E, Tabbara K, Hyndiuk R, editors. Diagnostic Microbiology and Cytology of the Eye. Boston: Butterworth Heinemann, 1995.

Bharathi, 2006, Br J Ophthalmol, Microbiological diagnosis of infective keratitis: Comparative evaluation of direct microcopy and culture results, 1271

Facklam RR, Carey RB. Streptococci and Aerococci. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ, editors. Manual of Clinical Microbiology. 4 th ed. Washington DC: American Society for Microbiology; 1985. p. 154-75.

National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Vol. 20. 4 th ed. Approval standard (document M7-A5). Villanova, PA: National Committee for Clinical Laboratory Standards; 2000.

Wolfson, 1985, Antimicrob Agents Chemother, The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro, 581

Hwang, 2004, Surv Ophthalmol, Fluoroquinolones resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolnes, S79

Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5% and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;122:466-9.

Mather, 2002, Am J Ophthalmol, Fourth generation fluoroquinolnes: new weapons in the arsenal of ophthalmic antibiotics, 463

Thornsberry, 1999, Antimicrob Agents Chemothera, Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S study, 2612

Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-5.